Answers are grounded in this paper and cite their sources.
There was a greater than 50% decline in central nervous system (CNS) drug discovery and development programs by major pharmaceutical companies from 2009 to 2014. This decline was paralleled by a rise in the number of university led drug discovery centers, many in the CNS area, and a growth in the number of public-private drug discovery partnerships. Diverse operating models have emerged as the academic drug discovery centers adapt to this changing ecosystem.
No takes yet. Share an insight, caveat, or question.
Yokley et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: